Agenus (AGEN) Reports ZOE-50 Phase 3 Met Primary Endpoint (GSK)
Tweet Send to a Friend
Agenus (NASDAQ: AGEN) announced that its partner GlaxoSmithKline (NYSE: GSK) reported that the ZOE-50 Phase 3 study met its primary ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
